Interferon down regulates the male-specific cytochrome P450IIIA2 in rat liver.
The aim of this study was to clarify the mechanism by which cytochrome P450 (P450)-mediated catalytic activity is decreased following interferon (IFN) administration. Microsomal steroid hydroxylation was assessed to test the hypothesis that IFN selectively decreases the activities of individual P450 isozymes in male rats. Thus, recombinant rat IFN gamma (r-rat IFN gamma) treatment produced 40% and 17% reductions in androst-4-ene-3,17-dione (androstenedione) 6 beta- and 16 beta-hydroxylation, respectively. Androstenedione 16 alpha- and 7 alpha-hydroxylation were unaltered following r-rat IFN gamma treatment. Similar changes in the androstenedione hydroxylation pathways were observed following administration of naturally derived rat IFN alpha/beta. Microsomal levels of P450IIIA2, the male-specific constitutive steroid 6 beta-hydroxylase, were lower after administration of r-rat IFN gamma (42% of control fractions). Furthermore, hepatic P450IIIA2 mRNA was found to be decreased to a similar extent by r-rat IFN gamma. These findings suggest that IFN selectively decreases the content of this isozyme by a mechanism involving altered mRNA regulation. Sex steroids were unlikely to have mediated the decrease in P450IIIA2 levels since serum estradiol and testosterone levels were unchanged by r-rat IFN gamma. In order to determine whether IFN alters the expression of P450IIIA1, a steroid-inducible member of the P450IIIA gene subfamily which is not expressed in untreated rat liver, adult female rats (which lack P450IIIA2) were coadministered pregnenolone 16 alpha-carbonitrile and r-rat IFN gamma. However, IFN failed to impair the induction of androstenedione 6 beta-hydroxylation produced by pregnenolone 16 alpha-carbonitrile. These findings suggest that although IFN decreases the expression of P450IIIA2, it may not down regulate the expression of other steroid-inducible P450IIIA proteins. In view of the existence of human P450IIIA orthologs which catalyze the metabolism of several important therapeutic agents, the findings of this study may help predict possible drug interactions in patients receiving IFN.
Department of Medicine, University of Sydney, Westmead Hospital, New South Wales, Australia.
P I
PI
Craig
I
I
Mehta
M
M
Murray
D
D
McDonald
A
A
Aström
P H
PH
van der Meide
G C
GC
Farrell
D000818:Animals; D003577:Cytochrome P-450 Enzyme System / Q000032:analysis* / Q000235:genetics; D015536:Down-Regulation; D004958:Estradiol / Q000097:blood; D005260:Female; D007372:Interferons / Q000494:pharmacology*; D007527:Isoenzymes / Q000032:analysis*; D008099:Liver / Q000201:enzymology*; D008297:Male; D011285:Pregnenolone Carbonitrile / Q000494:pharmacology; D011519:Proto-Oncogenes; D051381:Rats; D011919:Rats, Inbred Strains; D012737:Sex Factors; D013739:Testosterone / Q000097:blood
D007527:Isoenzymes; D011285:Pregnenolone Carbonitrile; D013739:Testosterone; D004958:Estradiol; D007372:Interferons; D003577:Cytochrome P-450 Enzyme System